Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1Phase EARLY_PHASE1 1Phase 3 1Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 10Thoracic 4Dermatologic 2Other solid neoplasm 1Other hematologic neoplasm 1Head & Neck 1

Conditions

Immune-related Adverse Event 1

Interventions

Cyclophosphamide 34Cytarabine 33Exercise 26Blood Specimen Collection 24venetoclax 23fludarabine phosphate 22Busulfan 22fludarabine 18Methotrexate 18Methods 18Cyclosporine 18Peripheral Blood Stem Cell Transplantation 17Filgrastim 17Antilymphocyte Serum 17Standard of Care 16Whole-Body Irradiation 15Granulocyte Colony-Stimulating Factor 15Educational Status 15Early Intervention, Educational 15Palliative Care 14Melphalan 14Daunorubicin 14Mycophenolic Acid 13Azacitidine 13Practice Guidelines as Topic 12Etoposide 12Dexamethasone 12Radiotherapy 11Interviews as Topic 10Vincristine 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Immune Checkpoint Inhibitors × Other hematologic neoplasm × Clear all
NCT06702566 2024-11-25

The Effect of Serum Ferritin in irAE

Tianjin Medical University Cancer Institute and Hospital

Phase NA Recruiting
1,500 enrolled
Other hematologic neoplasmOther solid neoplasm

Immune-related Adverse Event

Data powered by HemOnc (CC BY 4.0) Colophon âš¡